![]() |
|
|
Vol. 292, Issue 1, 326-330, January 2000
Clinical Pharmacology, St. Bartholomew's and the Royal London
School of Medicine and Dentistry, London (S.O., C.S., N.B.); and Bone
and Joint Research Group, Department of Postgraduate Medicine,
University of Bath, Bath (T.M., C.S., D.B.), United Kingdom
Xanthine oxidoreductase (XOR) is a mammalian enzyme that possesses a
series of redox centers, which use either NAD+ or molecular
oxygen for oxidation of the purines xanthine and hypoxanthine to uric
acid. The ability of XOR to act as an NADH oxidase is a less
well recognized function of the enzyme, and it is this function that we
used to explore the metabolism of glyceryl trinitrate. The antiplatelet
effect of nitric oxide (NO) on platelet aggregation was used as a
bioassay to assess the bioconversion of glyceryl trinitrate to NO by
XOR. The thromboxane mimetic U46619, 2 µM, was used to stimulate
platelet aggregation in platelet-rich plasma prepared from healthy
drug-free human volunteers. All incubations were carried out at 37°C
for 2 min after the addition of U46619. XOR produced a dose-dependent
antiaggregant effect when incubated with glyceryl trinitrate (GTN), 220 µM. This did not occur when GTN or XOR was incubated with
platelet-rich plasma independently. The antiaggregant effect of XOR
plus GTN was dose dependently inhibited by allopurinol, with an
IC50 of 100 µM. The addition of superoxide dismutase
(SOD), 100 U/ml produced a shift to the left in the antiaggregant
dose-response curve for XOR. The IC50 for XOR at 200 U/l
without SOD was decreased to 80 U/l with SOD. Oxyhemoglobin, an
extracellular NO scavenger, produced a dose-dependent, noncompetitive
inhibition of the antiaggregant effect of XOR plus GTN. These findings
suggest that GTN may be reduced to NO in vitro by the enzyme XOR in
sufficient amounts to inhibit platelet aggregation.
This article has been cited by other articles:
![]() |
J. V. Esplugues, M. Rocha, C. Nunez, I. Bosca, S. Ibiza, J. R. Herance, A. Ortega, J. M. Serrador, P. D'Ocon, and V. M. Victor Complex I Dysfunction and Tolerance to Nitroglycerin: An Approach Based on Mitochondrial-Targeted Antioxidants Circ. Res., November 10, 2006; 99(10): 1067 - 1075. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Oechslin, W. Kiowski, R. Schindler, A. Bernheim, B. Julius, and H. P. Brunner-La Rocca Systemic Endothelial Dysfunction in Adults With Cyanotic Congenital Heart Disease Circulation, August 23, 2005; 112(8): 1106 - 1112. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Daiber, M. Oelze, M. Coldewey, M. Bachschmid, P. Wenzel, K. Sydow, M. Wendt, A. L. Kleschyov, D. Stalleicken, V. Ullrich, et al. Oxidative Stress and Mitochondrial Aldehyde Dehydrogenase Activity: A Comparison of Pentaerythritol Tetranitrate with Other Organic Nitrates Mol. Pharmacol., December 1, 2004; 66(6): 1372 - 1382. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Hink, M. Oelze, P. Kolb, M. Bachschmid, M.-H. Zou, A. Daiber, H. Mollnau, M. August, S. Baldus, N. Tsilimingas, et al. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1826 - 1834. [Abstract] [Full Text] [PDF] |
||||